Arch Therapeutics, Inc.
ARTH
$0.20
$0.042627.07%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 132.33% | 91.02% | 628.57% | 2,368.75% | 111.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 132.33% | 91.02% | 628.57% | 2,368.75% | 111.11% |
| Cost of Revenue | 14.05% | 15.51% | 34.09% | 23,200.00% | 8.19% |
| Gross Profit | 288.46% | 590.48% | 295.61% | 1,057.14% | 52.29% |
| SG&A Expenses | 0.63% | -45.47% | 18.90% | -5.45% | 4.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.41% | -36.99% | 20.16% | -5.15% | 1.42% |
| Operating Income | -0.71% | 38.50% | -17.17% | 7.79% | -0.73% |
| Income Before Tax | -210.17% | -62.78% | -48.98% | -30.11% | -74.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -210.17% | -62.78% | -48.98% | -30.11% | -74.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -210.17% | -62.78% | -48.98% | -30.11% | -74.16% |
| EBIT | -0.71% | 38.50% | -17.17% | 7.79% | -0.73% |
| EBITDA | -0.69% | 38.52% | -17.17% | 7.78% | -0.80% |
| EPS Basic | -0.86% | 54.26% | 60.46% | 80.93% | -61.19% |
| Normalized Basic EPS | 10.67% | 54.26% | 60.46% | 80.93% | -61.21% |
| EPS Diluted | -0.86% | 54.26% | 60.46% | 80.93% | -61.19% |
| Normalized Diluted EPS | 10.67% | 54.26% | 60.46% | 80.93% | -61.21% |
| Average Basic Shares Outstanding | 247.22% | 255.90% | 276.78% | 582.49% | 8.04% |
| Average Diluted Shares Outstanding | 247.22% | 255.90% | 276.78% | 582.49% | 8.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |